Vinicio A. de Jesus Perez

Dr. Vinicio A. de Jesus Perez

Stanford University School of Medicine, Stanford, United States

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Pulmonary Circulation
Verified
Journal Article
Open access
BRBenoît Ranchoux
Benoît Ranchoux
LHLloyd Harvey
Lloyd Harvey
RARamon J. Ayon
Ramon J. Ayon
ABAleksandra Babicheva
Aleksandra Babicheva
SBSebastien Bonnet
Sebastien Bonnet
VPVinicio A. de Jesus Perez
Vinicio A. de Jesus Perez
Endothelial dysfunction is a major player in the development and progression of vascular pathology in pulmonary arterial hypertension (PAH), a disease associated with small vessel loss and obstructive vasculopathy that leads to increased pulmonary vascular resistance, subsequent right heart failure, and premature death. Over the past ten years, there has been tremendous progress in our understanding of pulmonary endothelial biology as it pertains to the genetic and molecular mechanisms that orchestrate the endothelial response to direct or indirect injury, and how their dysregulation can contribute to the pathogenesis of PAH. As one of the major topics included in the 2017 Grover Conference Series, discussion centered on recent developments in four areas of pulmonary endothelial biology: (1) angiogenesis; (2) endothelial‐mesenchymal transition (EndMT); (3) epigenetics; and (4) biology of voltage‐gated ion channels. The present review will summarize the content of these discussions and provide a perspective on the most promising aspects of endothelial dysfunction that may be amenable for therapeutic development.

15 March 2018 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
RZRoham T. Zamanian
Roham T. Zamanian
HHHaley Hedlin
Haley Hedlin
PGPaul Greuenwald
Paul Greuenwald
DWDavid M. Wilson
David M. Wilson
JSJoshua I. Segal
Joshua I. Segal
SKSteven M. Kawut
Steven M. Kawut
Rationale: Although amphetamines are recognized as “likely” agents to cause drug- and toxin-associated pulmonary arterial hypertension (PAH), (meth)amphetamine-associated PAH (Meth-APAH) has not been well described. Objectives: To prospectively characterize the clinical presentation, histopathology, and outcomes of Meth-APAH compared with those of idiopathic PAH (iPAH). Methods: We performed a prospective cohort study of patients with Meth-APAH and iPAH presenting to the Stanford University Pulmonary Hypertension Program between 2003 and 2015. Clinical, pulmonary angiography, histopathology, and outcomes data were compared. We used data from the Healthcare Cost and Utilization Project to estimate the epidemiology of PAH in (meth)amphetamine users hospitalized in California. Measurements and Main Results: The study sample included 90 patients with Meth-APAH and 97 patients with iPAH. Patients with Meth-APAH were less likely to be female, but similar in age, body mass index, and 6-minute-walk distance to patients with iPAH. Patients with Meth-APAH reported more advanced heart failure symptoms, had significantly higher right atrial pressure (12.7 ± 6.8 vs. 9.8 ± 5.1 mm Hg; P = 0.001), and had lower stroke volume index (22.2 ± 7.1 vs. 25.5 ± 8.7 ml/m2; P = 0.01). Event-free survival in Meth-APAH was 64.2%, 47.2%, and 25% at 2.5, 5, and 10 years, respectively, representing more than double the risk of clinical worsening or death compared with iPAH (hazard ratio, 2.04; 95% confidence interval, 1.28–3.25; P = 0.003) independent of confounders. California data demonstrated a 2.6-fold increase in risk of PAH diagnosis in hospitalized (meth)amphetamine users. Conclusions: Meth-APAH is a severe and progressive form of PAH with poor outcomes. Future studies should focus on mechanisms of disease and potential therapeutic considerations.

19 June 2019 in F1000Research
Verified
Journal Article
Open access
PDF file
DCDavid F Condon
David F Condon
NNNils P Nickel
Nils P Nickel
RARyan Anderson
Ryan Anderson
SMShireen Mirza
Shireen Mirza
VPVinicio A. de Jesus Perez
Vinicio A. de Jesus Perez
In February 2018, the 6th World Symposium on Pulmonary Hypertension (WSPH) brought together experts from various disciplines to review the most relevant clinical and scientific advances in the field of PH over the last 5 years. Based on careful review and discussions by members of the different task forces, major revisions were made on the hemodynamic definition for various forms of PH and new genes were added to the list of genetic markers associated with pulmonary arterial hypertension (PAH) and pulmonary veno-occlusive disease. In addition, the use of risk stratification tools was encouraged as a strategy to reduce one-year mortality risk in PAH patients through early implementation of PAH therapies. While members of the medical community are still debating some of the proposed changes, the new WSPH guidelines advocate early diagnosis and initiation of combination therapy to reduce mortality and improve quality of life in patients with PH.

1 May 2019 in Biomaterials
Verified
Journal Article
Closed access
ESElya A. Shamskhou
Elya A. Shamskhou
MKMichael J. Kratochvil
Michael J. Kratochvil
MOMark E. Orcholski
Mark E. Orcholski
NNNadine Nagy
Nadine Nagy
GKGernot Kaber
Gernot Kaber
VPVinicio A. de Jesus Perez
Vinicio A. de Jesus Perez

15 January 2020 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
NNNils P. Nickel
Nils P. Nickel
KYKe Yuan
Ke Yuan
PDPeter Dorfmuller
Peter Dorfmuller
SPSteeve Provencher
Steeve Provencher
YLYen-Chun Lai
Yen-Chun Lai
VPVinicio A. de Jesus Perez
Vinicio A. de Jesus Perez
Pulmonary arterial hypertension (PAH) is a disease characterized by progressive loss and remodeling of the pulmonary arteries, resulting in right heart failure and death. Until recently, PAH was seen as a disease restricted to the pulmonary circulation. However, there is growing evidence that patients with PAH also exhibit systemic vascular dysfunction, as evidenced by impaired brachial artery flow–mediated dilation, abnormal cerebral blood flow, skeletal myopathy, and intrinsic kidney disease. Although some of these anomalies are partially due to right ventricular insufficiency, recent data support a mechanistic link to the genetic and molecular events behind PAH pathogenesis. This review serves as an introduction to the major systemic findings in PAH and the evidence that supports a common mechanistic link with PAH pathophysiology. In addition, it discusses recent studies describing morphological changes in systemic vessels and the possible role of bronchopulmonary anastomoses in the development of plexogenic arteriopathy. On the basis of available evidence, we propose a paradigm in which metabolic abnormalities, genetic injury, and systemic vascular dysfunction contribute to systemic manifestations in PAH. This concept not only opens exciting research possibilities but also encourages clinicians to consider extrapulmonary manifestations in their management of patients with PAH.

27 January 2019 in Annual Review of Medicine
Verified
Journal Article
Closed access
ESEdda Spiekerkoetter
Edda Spiekerkoetter
SKSteven M. Kawut
Steven M. Kawut
VPVinicio A. de Jesus Perez
Vinicio A. de Jesus Perez
Pulmonary arterial hypertension (PAH) is a pulmonary vasculopathy that causes right ventricular dysfunction and exercise limitation and progresses to death. New findings from translational studies have suggested alternative pathways for treatment. These avenues include sex hormones, genetic abnormalities and DNA damage, elastase inhibition, metabolic dysfunction, cellular therapies, and anti-inflammatory approaches. Both novel and repurposed compounds with rationale from preclinical experimental models and human cells are now in clinical trials in patients with PAH. Findings from these studies will elucidate the pathobiology of PAH and may result in clinically important improvements in outcome.